Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMND304)

Drug Name
Miltefosine Drug Info
Synonyms
HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
Therapeutic ClassAntifungal Agents
Cross-matching ID
PubChem CID
3599
ChEBI ID
CHEMBL125
CAS Number
CAS 58066-85-6
TTD Drug ID
D00FGR
INTEDE Drug ID
DR1092
ACDINA Drug ID
D00436

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Asthma 1.69 5.17e-1 25/31 (80.65%) CD40;PRG2;FCER1G;...
D-Glutamine and D-glutamate metabolism 1.66 3.66e-1 5/5 (100%) GLUD1;GLUD2
RNA transport 1.59 5.27e-1 128/186 (68.82%) EIF2S3;EIF4A3;EIF4G1;...
Nitrogen metabolism 1.59 4.00e-1 16/17 (94.12%) CA2;GLUL;GLUD1;...
Allograft rejection 1.57 3.65e-1 32/38 (84.21%) CD40;GZMB;HLA-DMB;...
Proximal tubule bicarbonate reclamation 1.54 4.33e-1 21/23 (91.3%) CA2;GLUD1;GLUD2;...
Type I diabetes mellitus 1.53 3.77e-1 38/43 (88.37%) GZMB;HLA-DMB;HLA-DRB1;...
Neutrophil extracellular trap formation 1.53 3.43e-1 101/189 (53.44%) ELANE;HAT1;FCGR3B;...
Propanoate metabolism 1.50 3.91e-1 30/34 (88.24%) DLD;LDHC;HIBCH;...
Fc gamma R-mediated phagocytosis 1.49 3.99e-1 79/97 (81.44%) GSN;FCGR3B;MARCKS;...
IL-17 signaling pathway 1.46 4.61e-1 84/94 (89.36%) S100A9;CXCL5;S100A7;...
Graft-versus-host disease 1.45 4.31e-1 32/42 (76.19%) GZMB;HLA-DMB;HLA-DRB1;...
Glyoxylate and dicarboxylate metabolism 1.45 4.06e-1 23/30 (76.67%) GLUL;GLDC;CS;...
Glutamatergic synapse 1.42 4.55e-1 97/114 (85.09%) GNG11;GLUL;SLC1A1;...
Antigen processing and presentation 1.41 4.68e-1 60/78 (76.92%) HSPA4;HSP90AA1;CANX;...
Viral protein interaction with cytokine and cytokine re... 1.41 4.52e-1 84/100 (84%) CXCL5;CXCL8;PF4;...
Chemokine signaling pathway 1.39 4.86e-1 163/192 (84.9%) GNG11;CXCL5;CXCL8;...
Ferroptosis 1.39 4.62e-1 36/41 (87.8%) SLC39A14;MAP1LC3B;ACSL1;...
Fatty acid biosynthesis 1.37 5.13e-1 16/18 (88.89%) ACSL1;CBR4;ACSL4;...
Staphylococcus aureus infection 1.36 5.32e-1 72/95 (75.79%) DEFA4;FCGR3B;DEFB1;...
Arginine biosynthesis 1.35 5.37e-1 17/22 (77.27%) ARG1;GLUL;GLUD1;...
Alanine, aspartate and glutamate metabolism 1.31 6.70e-1 27/37 (72.97%) ALDH5A1;GLUL;GLUD1;...
Phosphonate and phosphinate metabolism 1.29 7.10e-1 5/6 (83.33%) CHPT1;PCYT2;CEPT1
Gastric acid secretion 1.28 7.33e-1 63/76 (82.89%) CA2;KCNJ15;EZR;...
RNA degradation 1.27 7.30e-1 53/79 (67.09%) PFKL;BTG3;DCP2;...
Autoimmune thyroid disease 1.27 7.13e-1 46/53 (86.79%) CD40;GZMB;HLA-DMB;...
Adherens junction 1.26 7.02e-1 63/71 (88.73%) INSR;LEF1;TGFBR2;...
Amino sugar and nucleotide sugar metabolism 1.22 7.35e-1 38/48 (79.17%) CYB5R2;UGDH;AMDHD2;...
GABAergic synapse 1.22 7.37e-1 76/89 (85.39%) GNG11;GLUL;PRKCB;...
Fluid shear stress and atherosclerosis 1.22 7.25e-1 123/139 (88.49%) SDC2;IL1R1;MMP9;...
Neurotrophin signaling pathway -1.19 5.51e-1 107/119 (89.92%) NTRK1;MAPK9;NFKBIE;...
Other types of O-glycan biosynthesis -1.22 5.34e-1 29/47 (61.7%) GALNT3;GALNT14;B4GALT3;...
Arginine and proline metabolism -1.23 5.06e-1 39/50 (78%) NOS2;ALDH4A1;ALDH3A2;...
Glycosaminoglycan biosynthesis -1.24 4.91e-1 40/58 (68.97%) CHPF2;EXTL3;HS3ST3A1;...
Lysosome -1.25 4.94e-1 115/128 (89.84%) HYAL1;ATP6AP1;NAGLU;...
Prion disease -1.27 4.38e-1 209/273 (76.56%) RYR1;PSMC3;SDHA;...
Breast cancer -1.27 4.47e-1 119/147 (80.95%) HRAS;FGF17;DVL1;...
Insulin resistance -1.27 4.57e-1 96/108 (88.89%) NR1H3;MLXIP;NR1H2;...
Glycerophospholipid metabolism -1.27 4.71e-1 71/98 (72.45%) CDIPT;CDS2;AGPAT4;...
Renal cell carcinoma -1.28 4.80e-1 68/69 (98.55%) HRAS;PRCC;PAK6;...
Phenylalanine metabolism -1.28 4.83e-1 14/17 (82.35%) AOC3;TAT;MAOB;...
Glutathione metabolism -1.28 4.99e-1 43/57 (75.44%) GGT1;SRM;GPX2;...
Dilated cardiomyopathy -1.28 5.09e-1 86/96 (89.58%) SGCA;TNNT2;CACNB3;...
Salivary secretion -1.29 5.09e-1 76/93 (81.72%) CST4;ADRA1B;PRKCA;...
Glycosaminoglycan degradation -1.30 5.08e-1 19/19 (100%) HYAL1;NAGLU;HGSNAT;...
Focal adhesion -1.30 5.08e-1 180/201 (89.55%) ACTN4;PAK6;AKT1;...
Longevity regulating pathway -1.31 5.04e-1 90/151 (59.6%) HRAS;ULK1;TSC2;...
Gastric cancer -1.32 4.98e-1 122/149 (81.88%) HRAS;FGF17;DVL1;...
Endometrial cancer -1.34 4.66e-1 56/58 (96.55%) AKT1;GADD45G;PTEN;...
Colorectal cancer -1.34 4.91e-1 84/86 (97.67%) AKT1;CYCS;GADD45G;...
JAK-STAT signaling pathway -1.35 4.81e-1 146/162 (90.12%) CISH;IL9;IFNA1;...
p53 signaling pathway -1.35 4.93e-1 63/73 (86.3%) CCNB2;CCNE1;PPM1D;...
Melanoma -1.36 5.15e-1 68/72 (94.44%) HRAS;FGF17;FGF4;...
Small cell lung cancer -1.37 5.11e-1 90/92 (97.83%) AKT1;CYCS;GADD45G;...
Thyroid cancer -1.38 5.11e-1 36/37 (97.3%) NTRK1;HRAS;GADD45G;...
Chronic myeloid leukemia -1.38 5.42e-1 72/76 (94.74%) HRAS;NFKBIA;PTPN11;...
Vascular smooth muscle contraction -1.40 5.02e-1 113/133 (84.96%) ADRA1D;PRKCQ;NPPC;...
Glycine, serine and threonine metabolism -1.40 5.43e-1 31/40 (77.5%) AGXT;PIPOX;SRR;...
Cocaine addiction -1.42 5.24e-1 42/49 (85.71%) GRIN2A;CREB3L1;GRIN2D;...
Steroid hormone biosynthesis -1.46 5.48e-1 43/61 (70.49%) SULT2B1;DHRS11;UGT2B17;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H